Juno Therapeutics To Report Third Quarter 2016 Financial Results On Wednesday, November 9

Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the third quarter 2016 on Wednesday, November 9, 2016, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern Time (ET).

Analysts and investors can participate in the conference call by dialing (855) 780-7198 for domestic callers and (631) 485-4870 for international callers, using the conference ID# 7555725.

The webcast can be accessed live on the Investor Relations page of Juno's website, www.JunoTherapeutics.com, and will be available for replay for 30 days following the call.

About Juno

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from some of the world's leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children's Research Institute, the University of California, San Francisco, and The National Cancer Institute. Juno Therapeutics has an exclusive license to the St. Jude Children's Research Hospital patented technology for CD19 directed product candidates that use 4-1BB, which was developed by Dario Campana, Chihaya Imai, and St. Jude Children's Research Hospital.

If you liked this article you might like

Intercept Sinks on Safety Issue, One Analyst Says Buy Anyway - Biotech Movers

FDA OKs BioCryst's Rapivab for Pediatric Indication - Biotech Movers

Biotech Leaders Join Corporate Chorus Angry Over Trump's DACA Move

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Entry Points Are Tough, and Post-Labor Day Action Is Historically Poor